Q1 FY27 results analysis · August 07, 2026

Emcure Pharmaceuticals Ltd Q1 FY27 Results Analysis: Revenue Surges 23%, Gross Margin Compresses 340 bps

+42.0%PAT year on year, Rs. 292.49 Cr
Cofacto ResearchPublished August 07, 20262 min readPositive read
Quick summary

Emcure Pharmaceuticals Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 2,580.45 Cr (+22.85% YoY) and PAT growth of +42.05% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateAugust 06, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 2,580.45 Cr (+22.85% YoY)
PAT (Q1)Rs. 292.49 Cr (+42.05% YoY)
EBITDA margin19.69% (+50 bps YoY)
EPS (Q1)Rs. 15.50 (+41.94% YoY)
Market capRs. 36,735.35 Cr
CMPRs. 1,936.70

Quarter Snapshot

EMCURE delivered a strong Q1 with revenue growth of 22.85% YoY, nearly double its guided low-to-mid teens range, driven by a 34.2% surge in international business. Operating leverage was evident as employee costs grew only 4.1%. However, gross margin compressed 340 bps due to input cost inflation and mix shift, and domestic growth lagged the market.

Key Investment Insights

Key Positives

  • Revenue grew 22.85% YoY to Rs.2,580.45 Cr, nearly double the guided low-to-mid teens range
  • PAT attributable to owners grew 42.05% YoY to Rs.293.98 Cr
  • International revenue grew 34.2% YoY, with all three regions (RoW, Europe, Canada) posting >24% growth
  • EBITDA margin expanded 50 bps YoY to 19.7%
  • Employee costs grew only 4.1% YoY, demonstrating operating leverage
  • Adjusted PAT grew 33.8% YoY, confirming clean operating momentum

Risk Factors

  • Domestic revenue grew 10.2% YoY, below IPM growth of ~12% and below management's aspiration of industry +100-200 bps
  • Gross margin compressed 340 bps YoY to 58.4% due to input cost inflation (solvents +30%) and mix shift toward lower-margin international markets
  • Freight cost headwinds flagged in pre-call note, though other expenses grew below revenue

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.